Coagulopathies in Patients with Liver Cirrhosis Presenting to DHQ Teaching Hospital, Dera Ismail Khan: Coagulopathies in Liver Cirrhosis Patients

Salman Khan; Moeen Ul Haq; Tahira Atta; Ahmad Rizwan; Gulshan Munir; Syed Rehman

doi:10.54393/pjhs.v5i10.1726

Authors

Salman Khan Department of Medicine, District Headquarter Teaching Hospital, Dera Ismail Khan, Pakistan
Moeen Ul Haq Department of Gastroenterology, Gomal Medical College, Dera Ismail Khan, Pakistan
Tahira Atta Department of Pathology, Khyber Medical University, Institute of Medical Sciences, Kohat, Pakistan
Ahmad Rizwan Department of Pathology, Jinnah Medical College, Peshawar, Pakistan
Gulshan Munir Department of Hematology, Hayatabad Medical Complex, Peshawar, Pakistan
Syed Rehman Department of Medicine, District Headquarter Teaching Hospital, Dera Ismail Khan, Pakistan

DOI:

https://doi.org/10.54393/pjhs.v5i10.1726

Keywords:

Liver Cirrhosis, Fibrinogen, Platelet Count, D- Dimer, Intravascular Coagulation

Abstract

The liver develops fibrosis and nodules due to persistent damage, altering its natural lobular organization, known as cirrhosis. Various assaults such as toxic substances, viral infections, autoimmunity, or genetic disorders can damage the liver. Each lesion leads to fibrosis, or scar tissue formation, initially maintaining its functionality. Objective: To determine the frequency of coagulopathies occurring in patients with liver cirrhosis. Methods: This descriptive cross-sectional study was conducted in the General Medicine department at DHQ Teaching Hospital, D.I Khan, from June 12, 2022, to December 12, 2022. A total of 240 patients were recruited using non-probability consecutive sampling to determine the frequency of coagulopathies occurring in patients with liver cirrhosis. Coagulation tests, including prothrombin time and activated partial thromboplastin time, were performed. Data on age, gender, diabetes mellitus, hypertension, smoking status, and coagulopathies were recorded on a pre-designed proforma. Analysis was done using SPSS 20.0. Means and standard deviations were calculated for age and frequencies and percentages for categorical variables. Coagulopathies were stratified by gender, diabetes, hypertension, and smoking status to assess effect modifications. Post-stratification chi-square tests were applied, with P < 0.05 as significant. Results: The mean age was 45.56 ± 3.357 years. Males comprised 127 (52.9%) and females 113 (47.1%). Age distribution was 12.9% (20-30 years), 24.6% (31-40 years), 47.5% (41-50 years), and 15.0% (51-60 years). Coagulopathies were present in 74 (30.8%) patients, while 166 (69.2%) had none. Ninety patients (37.5%) had normal PT, lasting less than 15 seconds (mean + SD = 11.28 ± 2.02 sec), while 121 patients (50.4%) had prolonged PT (mean + SD = 22.94 ± 5.93 sec) and indicates a statistically significant difference of PT. Conclusion: Patients with cirrhosis had significantly higher and prolonged PT and APTT values, indicating an increased risk of coagulopathies.

References

Tanwar S, Rhodes F, Srivastava A, Trembling PM, Rosenberg WM. Inflammation and fibrosis in chronic liver diseases including non-alcoholic fatty liver disease and hepatitis C. World Journal of Gastroenterology. 2020 Jan; 26(2): 109. doi: 10.3748/wjg.v26.i2.109.

Zermatten MG, Fraga M, Moradpour D, Bertaggia Calderara D, Aliotta A et al. Hemostatic alterations in patients with cirrhosis: from primary hemostasis to fibrinolysis. Hepatology. 2020 Jun; 71(6): 2135-48. doi: 10.1002/hep.31201.

GinËs P, Krag A, Abraldes JG. Sol‡ E, Fabrellas N, Kamath PS. Liver Cirrhosis. Lancet. 2021 Oct; 398(10308): 1359-76. doi: 10.1016/S0140-6736(21)01374-X.

Sepanlou SG, Safiri S, Bisignano C, Ikuta KS, Merat S, Saberifiroozi M et al. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet Gastroenterology & Hepatology. 2020 Mar; 5(3): 245-66. doi: 10.1016/S2468-1253(19)30349-8.

Huang DQ, Terrault NA, Tacke F, Gluud LL, Arrese M, Bugianesi E et al. Global epidemiology of cirrhosis-aetiology, trends and predictions. Nature Reviews Gastroenterology & Hepatology. 2023 Jun; 20(6): 388-98. doi: 10.1038/s41575-023-00759-2.

Islam R, Kundu S, Jha SB, Rivera AP, Monar GV, Islam H, Puttagunta SM, Sange I. Cirrhosis and coagulopathy: mechanisms of hemostasis changes in liver failure and their management. Cureus. 2022 Apr;14(4). doi: 10.7759/cureus.23785.

Kim A, Niu B, Woreta T, Chen PH. Clinical considerations of coagulopathy in acute liver failure. Journal of Clinical and Translational Hepatology. 2020 Dec 12;8(4):407. doi: 10.14218/JCTH.2020.00058.

Gracia-Sancho J, Caparrós E, Fernández-Iglesias A, Francés R. Role of liver sinusoidal endothelial cells in liver diseases. Nature reviews Gastroenterology & Hepatology. 2021 Jun; 18(6): 411-31. doi: 10.1038/s41575-020-00411-3.

Ren W, Zhang J, Chen Y, Wen M, Su Y, Zhao Y et al. Evaluation of coagulation, fibrinolysis and endothelial biomarkers in cirrhotic patients with or without portal venous thrombosis. Clinical and Applied Thrombosis/Hemostasis. 2020 Dec; 26: 1076029620982666. doi: 10.1177/1076029620982666.

La Mura V, Bitto N, Tripodi A. Rational hemostatic management in cirrhosis: from old paradigms to new clinical challenges. Expert Review of Hematology. 2022 Dec; 15(12): 1031-44. doi: 10.1080/17474086.2022.2144217.

Chen H, Liu L, Qi X, He C, Wu F, Fan D et al. Efficacy and safety of anticoagulation in more advanced portal vein thrombosis in patients with liver cirrhosis. European Journal of Gastroenterology & Hepatology. 2016 Jan; 28(1): 82-9. doi: 10.1097/MEG.0000000000000482.

Wan J, Konings J, de Laat B, Hackeng TM, Roest M. Added value of blood cells in thrombin generation testing. Thrombosis and Haemostasis. 2021 Dec; 121(12): 1574-87. doi: 10.1055/a-1450-8300.

Gish RG, Regenstein FG, Flamm SL, Stravitz RT, Brothers JM. Guidance for coagulation management in patients with acute or chronic liver failure. Gastroenterol. Hepatol. 2021 Jan; 17: 3-26.

Ruberto MF, Piras MS, Sorbello O, Civolani A, Usai P, Fanni D et al. Chronic intravascular coagulation in liver cirrhosis predicts a high hemorrhagic risk. European Review for Medical & Pharmacological Sciences. 2021 Sep; 25(17): 5518-5524. doi: 10.26355/eurrev_202109_26663.

Zhong HJ, Xiao P, Lin D, Zhou HM, He XX. Cirrhosis in Wilson disease is characterized by impaired hepatic synthesis, leukopenia and thrombocytopenia. International Journal of Medical Sciences. 2020 May; 17(10): 1345. doi: 10.7150/ijms.44338.

Hazim AZ, Ruan GJ, Khodadadi RB, Slusser JP, Marshall AL, Pruthi RK. A single‐institution retrospective study of causes of prolonged prothrombin time and activated partial thromboplastin time in the outpatient setting. International Journal of Laboratory Hematology. 2022 Feb; 44(1): 209-15. doi: 10.1111/ijlh.13727.

Vecerzan L, Olteanu A, Maniu I, Boicean A, Cipăian CR, Dura H et al. Thrombin generation in chronic liver diseases-a pilot study. InHealthcare 2021 May; 9(5): 550. doi: 10.3390/healthcare9050550.

Bohania N, Agrawal A, Prakash A, Nangia A, Kumar A. Coagulation profile and its correlation with severity of liver dysfunction and gastrointestinal bleed in alcoholic liver disease patients. Journal Association Physicians India. 2021 Jun; 69(6): 11-2.

Bulut Y, Sapru A, Roach GD. Hemostatic balance in pediatric acute liver failure: epidemiology of bleeding and thrombosis, physiology, and current strategies. Frontiers in Pediatrics. 2020 Dec; 8: 618119. doi: 10.3389/fped.2020.618119.

Sadamatsu K, Kugai T, Eto Y, Muta M, Maeda T, Ishimatsu T, et al. Manual compression hemostasis using a hemostatic pad for the distal radial artery approach. Cardiovascular Revascularization Medicine. 2024 May. doi: 10.1016/j.carrev.2024.05.028.